OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze
Episode Details
The recent episode of the All-In Podcast featured a wide-ranging discussion led by hosts Jason Calacanis, David Friedberg, David Sacks, and Chamath Palihapitiya. They started by analyzing how OpenAI, under Sam Altman, alongside Sarah Frier and Greg Brockman, reportedly missed targets for ChatGPT. However, the company is advancing rapidly with GPT 5.5 and the Codex model, keeping them competitive against anthropic and its CEO Dario Amodei, who are managing compute constraints with Claude and Opus 4.7. Elon Musk continues to challenge the landscape with Grok and leveraging computing excess from SpaceX, all while pursuing Elon Musk's lawsuit against OpenAI. The hosts highlighted how Hyperscalers like Google (pushing Gemini), Microsoft, Amazon, Meta, and Oracle are driving a historic Capex Boom centered around Cloud Computing. This massive AI Infrastructure Buildout is creating unprecedented Energy demand for AI, prompting interest in highly efficient SLMs (Small Language Models). In the developer space, Aaron Levie criticized the hype around Vibe Coding, noting risks highlighted when a non-engineer using Cursor 2.0 accidentally deleted a codebase. In the enterprise software sector, Cybersecurity in the AI era is exploding. Executives like George Kurtz of CrowdStrike and leaders at Palo Alto Networks see immense opportunities to defend against both domestic threats and foreign models like China's Deep Seek, as well as sophisticated models like Anthropic's Mythos. Shifting to biotechnology, the conversation covered the explosive popularity of GLP-1 Agonists. Eli Lilly is seeing massive success with Tirzepatide and is now testing the next-generation peptide Retatrutide. Finally, the episode concluded with a look at the Supreme Court, where the hosts discussed oral arguments involving Bayer and the EPA. This high-stakes case is deeply influenced by the recent overturning of the Chevron Doctrine and ongoing debates over Federal Preemption.
The episode explores the intense competition in AI infrastructure, focusing on the massive capital expenditure by hyperscalers and the strategic pivot toward energy-efficient models. It also highlights the rapid growth of the GLP-1 peptide market and the legal complexities surrounding the Supreme Court's role in federal regulatory preemption.
Generated with gemini-3.1-flash-lite on 7/19/2026, 5:40:45 AM. For research only. Not financial advice.Hyperscaler AI Infrastructure Buildout
The massive capital expenditure by hyperscalers is a necessary, long-term investment in the foundational infrastructure of the modern economy.
Hyperscalers are prioritizing AI infrastructure over short-term free cash flow, signaling a structural shift in capital allocation toward compute and energy capacity.
- Combined 2026 capex guidance of $725 billion from Amazon, Microsoft, Google, and Meta.
- Google Cloud revenue grew 63% year-over-year.
- AI is estimated to be generating 75% of current GDP growth.
- Continued growth in cloud revenue metrics
- Successful deployment of energy-efficient SLMs (Small Language Models)
- Advancements in grid infrastructure and power generation
- Potential for over-investment similar to the 2000s fiber optic buildout
- Regulatory and environmental pushback against data center energy consumption
- Diminishing returns on compute-heavy model training
- Analyze the ratio of capex to operating cash flow across the Mag 7
- Monitor power purchase agreement (PPA) trends for data centers
- Track adoption rates of small language models (SLMs) as an efficiency metric
Next-Generation Peptide Therapeutics
The next generation of multi-agonist peptides will expand the addressable market for metabolic health beyond current GLP-1 treatments.
New peptides like Retatrutide show superior efficacy in fat loss and metabolic markers compared to existing dual-agonist treatments, suggesting a significant upgrade cycle in the pharmaceutical market.
- Phase 3 trial data for Retatrutide showed 80% reduction in liver fat and significant weight loss.
- Clinical data indicates potential for muscle maintenance alongside fat loss.
- High demand for metabolic health solutions is driving massive market interest.
- FDA approval milestones for next-gen peptides
- Expansion of insurance coverage and Medicare pricing agreements
- Positive clinical data on anti-inflammatory and longevity benefits
- Regulatory hurdles and long-term safety data requirements
- Potential for supply chain constraints
- Pricing pressure from government and insurance payers
- Review upcoming FDA regulatory calendar for peptide approvals
- Assess competitive landscape for multi-agonist vs dual-agonist drugs
- Monitor pricing trends for GLP-1 agonists under Medicare
Watchlist
- Hyperscaler capex guidance
- Energy spot rates for data center hubs
- Retatrutide FDA approval timeline
- OpenAI IPO probability metrics
- Supreme Court rulings on federal preemption
Open Questions
- Will the current AI infrastructure buildout lead to a 'dark fiber' style glut or sustained utilization?
- Can algorithmic pruning techniques realistically reduce inference costs by 10x without sacrificing model utility?
- How will the Supreme Court's stance on federal preemption impact the liability landscape for chemical and pharmaceutical manufacturers?
Key Topics & People
The delivery of computing services over the internet, critical for hosting AI models.
.jpg?width=300){kind=avatar}
The intersection of AI capabilities and cybersecurity, raising concerns about automated vulnerabilities.
CEO of Anthropic, noted for navigating regulatory hurdles surrounding AI model releases.
Investor and podcast host offering insights on geopolitical conflicts, US policy, and politics.
.jpg?width=300){kind=avatar}
Investor and podcast host analyzing AI infrastructure, politics, and markets.
.jpg?width=300){kind=avatar}
Investor and podcast host moderating discussions on startups and tech markets.
Host of the All-In Podcast conducting the interview with Ryan Cohen.
The podcast hosting the interview with GameStop CEO Ryan Cohen.
Large cloud service providers that stand to gain an oligopoly through heavy AI regulation.
.jpg?width=300){kind=avatar}
CEO of OpenAI.
.jpg?width=300){kind=avatar}
Cybersecurity company whose CEO tested Anthropic's models.
A cybersecurity company and portfolio investment of Section 32.
_(cropped).jpg?width=300){kind=avatar}
President and co-founder of OpenAI, known for his foresight on compute needs.
An OpenAI model focused on coding assistance that rapidly scaled to 5 million users.
CFO of OpenAI who discusses the company's recent fundraising, infrastructure strategies, and market positioning.
The practice of building software and applications using AI language models rather than writing code manually.
The massive capital expenditure cycle dedicated to constructing data centers, deploying GPUs, and powering AI development.
A new triple-agonist peptide drug by Eli Lilly showing spectacular fat loss and liver health improvements.
The principle that federal laws supersede state laws, heavily debated in current corporate product liability cases.
A recently overturned legal precedent regarding federal agency deference that impacts corporate regulations.
The highest federal court in the US, currently ruling on complex corporate regulation cases.
A class of peptide medications that manage blood sugar and drive significant weight loss.
A dual-agonist GLP-1 and GIP drug marketed by Eli Lilly for metabolic health.
CEO of CrowdStrike, discussing the immense enterprise demand for AI-driven security tools.
Tech CEO who criticized the unrealistic expectations of unmanaged vibe coding by non-engineers.
An AI-assisted code editor used heavily for agentic software development and vibe coding.
More efficient, localized AI models designed to reduce energy inference costs.
The massive electrical power required to operate advanced AI compute facilities.
The massive surge in capital expenditures by tech companies to build AI capabilities.
A high-stakes trial where Elon Musk accuses OpenAI of unjust enrichment and abandoning its nonprofit mission.